STOCK TITAN

Outcry Grows Over Proposed Bayer AG Settlement of Monsanto Roundup Cancer Lawsuits

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary

On March 5, 2021, a federal judge was urged by cancer victims to reject a proposed settlement regarding Roundup lawsuits against Bayer AG (OTCMKTS: BAYRY). The motion highlights concerns over existing settlements favoring certain plaintiffs while excluding others diagnosed post-February 3, 2021. Critics argue this settlement protects Bayer and undermines due-process rights, potentially limiting compensation for future claimants. The ongoing multidistrict litigation focuses on cancer claims related to glyphosate exposure, with significant implications for those affected by Roundup.

Positive
  • Bayer's willingness to negotiate settlements indicates engagement in the litigation process.
Negative
  • The proposed settlement limits future claimants' ability to participate in litigation and seek punitive damages.
  • Criticism of the settlement suggests it primarily benefits Bayer and class counsel, potentially undermining public trust.
  • The motion argues that the artificial cut-off date for claims is unfair to future victims of Roundup exposure.

SAN FRANCISCO, March 5, 2021 /PRNewswire/ -- Cancer victims are asking a federal judge overseeing thousands of Roundup weed killer cancer lawsuits to reject a proposed settlement that would allow the glyphosate-based herbicide to remain on store shelves while shielding Bayer AG (OTCMKTS: BAYRY) from future cancer lawsuits. 

A motion filed Thursday by trial lawyers at Dallas-based Fears Nachawati Law Firm shines a light on growing criticism of some plaintiffs' lawyers who have already negotiated with Bayer AG to obtain favorable settlements for their existing clients that – based on the proposed settlement – would not be available to individuals not yet diagnosed.

Under the proposed settlement described in the motion as "a one-way street" that benefits only Bayer, individuals filing a cancer claim after Feb. 3, 2021, could not participate in class-action litigation and seek punitive damages in litigation. Instead, they would be limited to compensation based on a multitiered formula.

The plaintiffs challenging the settlement include three individuals who were diagnosed with non-Hodgkin's lymphoma after exposure to Roundup and who had not filed a lawsuit by Feb. 3.

"It is fundamentally unfair, and at odds with basic due-process protections, to force someone to opt out now when she has no idea what her circumstances might be if she becomes injured," the motion states. 

"This proposed settlement is opposed by those most familiar with the litigation of cases involving dangerous products like Roundup because they recognize that this proposal would benefit Monsanto and class counsel at the expense of millions of people exposed to Roundup," the motion states. "This is not a real lawsuit, but an effort to create an alternative dispute resolution mechanism in the guise of a class-action settlement." 

"There is no good reason why the class is limited to those who have already been exposed when Monsanto has no intention of stopping the sale of Roundup, or changing its composition, so that thousands of individuals will continue to run the risk of contracting [non-Hodgkin's lymphoma] from Roundup through post-February 3, 2021 exposure. If this were a real lawsuit, why would any class representative (or class counsel) create a wholly artificial cut-off date and not include everyone who will be exposed to Roundup in the future?" 

The multidistrict litigation (MDL) is In re Roundup Products Liability Litigation, case number 3:16-md-02741, in the U.S. District Court for the Northern District of California. 

Dallas-based Fears Nachawati Law Firm represents more than 4,000 individual plaintiffs in active litigation against Bayer and continues to investigate new claims on behalf of those sickened after exposure to Roundup. For the past three years, the law firm was ranked number one nationally in product liability filings in federal court. For more information, visit https://www.fnlawfirm.com/.  

Contact:
Robert Tharp
Androvett Legal Media
214-458-4007

Cision View original content:http://www.prnewswire.com/news-releases/outcry-grows-over-proposed-bayer-ag-settlement-of-monsanto-roundup-cancer-lawsuits-301241778.html

SOURCE Fears Nachawati Law Firm

FAQ

What is the recent controversy surrounding Bayer AG regarding Roundup lawsuits?

Cancer victims are challenging a proposed settlement that allows Roundup to remain on shelves while protecting Bayer from future lawsuits.

Why are cancer victims opposing Bayer's proposed settlement for Roundup?

They argue the settlement unfairly limits the rights of future claimants diagnosed after February 3, 2021, and primarily benefits Bayer.

What implications does the proposed settlement have for future Roundup claimants?

Individuals filing claims after February 3, 2021, would be restricted to a compensation formula and unable to seek punitive damages.

Who represents the plaintiffs in the Roundup litigation against Bayer?

The Fears Nachawati Law Firm represents over 4,000 plaintiffs affected by Roundup and is investigating new claims.

What is the status of the Roundup Products Liability Litigation?

The litigation is ongoing in the U.S. District Court for the Northern District of California under the case number 3:16-md-02741.

BAYER AG S/ADR

OTC:BAYRY

BAYRY Rankings

BAYRY Latest News

BAYRY Stock Data

27.39B
3.93B
0.19%
Drug Manufacturers - General
Healthcare
Link
United States of America
Leverkusen